Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18069433 | 0.82 | TGFBR1 (0.70) | TGFBR1 | |
| SCHEMBL5138799 | 0.82 | TGFBR1 (0.69) | TGFBR1MAPK14 | |
| SCHEMBL18005423 | 0.81 | TGFBR1 (1.00) | TGFBR1MAPK14 | |
| SCHEMBL15637808 | 0.77 | TGFBR1 (0.62) | TGFBR1MAPK14 | |
| SCHEMBL18005295 | 0.75 | TGFBR1 (1.00) | TGFBR1MAPK14 | |
| SCHEMBL15638339 | 0.70 | TGFBR1 (0.81) | TGFBR1MAPK14 | |
| SCHEMBL28019362 | 0.70 | TGFBR1 (0.64) | TGFBR1 | |
| SCHEMBL15639333 | 0.69 | TGFBR1 (0.64) | TGFBR1MAPK14 | |
| SCHEMBL30117529 | 0.69 | TGFBR1 (0.64) | TGFBR1MAPK14 | |
| SCHEMBL18005346 | 0.69 | TGFBR1 (1.00) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981944-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC (US) | 2018-05-29 | — | — | US | claimed |
| EP-3259264-A1 | GDF-8 INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-12-27 | — | — | EP | claimed |
| US-20160264553-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-15 | — | — | US | claimed |
| WO-2016133838-A1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-25 | — | — | WO | claimed |
| US-9981944-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981944-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981944-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3259264-A1 | GDF-8 INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-12-27 | — | — | EP | disclosed |
| US-20160264553-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-15 | — | — | US | disclosed |
| US-20160264553-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-15 | — | — | US | disclosed |
| US-20160264553-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-15 | — | — | US | disclosed |
| WO-2016133838-A1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016133838-A1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264553-A1 | GDF-8 Inhibitors | CXCL8, MSTN, LGALS8 | TGFBR1 249/4885MAPK14 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.